Amgen Inc(AMGN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low334.05
Day High345.00
Open:344.38
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?
Tipranks
Analysts’ Top Healthcare Picks: Dr Reddy’s Laboratories (RDY), Amgen (AMGN)
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Neumora Therapeutics, Inc. (NMRA) and Amgen (AMGN)
Stock Target Advisor
Market Analysis: June 15th, 2026
Market Analysis: June 15th, 2026
Tipranks
Amgen’s ABP 938 Takes Aim at EYLEA HD in High-Stakes Eye Disease Trial
Tipranks
Amgen’s MARITIME-SWITCH Trial Targets GLP-1 Switchers in the Growing Obesity Drug Market
Motley Fool
AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend.
Tipranks
Bernstein Remains a Hold on Amgen (AMGN)
Zacks Investment Research
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
Zacks Investment Research
Can Amgen's MariTide Win Share in the Fast-Growing Obesity Market?
Can Amgen's MariTide Win Share in the Fast-Growing Obesity Market?
StockStory
2 S&P 500 Stocks with Competitive Advantages and 1 Facing Challenges
AMGN
Zacks Investment Research
Sanofi Wins EU Nod for Subcutaneous Sarclisa in Multiple Myeloma
Sanofi Wins EU Nod for Subcutaneous Sarclisa in Multiple Myeloma
Motley Fool
The Smartest Dividend ETF to Buy With $1,000 Right Now -- and It's Up 19% in 2026
Tipranks
Analysts Offer Insights on Healthcare Companies: Novartis (NVS), Amgen (AMGN) and Bristol-Myers Squibb (BMY)
Motley Fool
Amgen: A Biotech Giant's Path to Recovery and Growth
Zacks Investment Research
Can JNJ Sustain Growth Amid Patent, Legal and China Risks?
Can JNJ Sustain Growth Amid Patent, Legal and China Risks?
MarketBeat
Amgen Touts MariTide, AI Gains and 2026 Growth Plans at Jefferies Conference
MarketBeat.com
Tipranks
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Thermo Fisher (TMO)
StockStory
2 Unpopular Stocks That Should Get More Attention and 1 We Question
AMGN

Profile

Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two next-generation products, Aranesp & Neulasta and also a biosimilar drug, Prolia/Xgeva. The acquisition of Immunex Corp gave Amgen access to the multi-blockbuster drug, Enbrel. Other products are Repatha, Blincyto, Parsabiv, Evenity, Aimovig, Lumakras/Lumykras, Kanjinti, Mvasi & Amgevita biosimilars. Amgen also has a promising pipeline of cancer drugs. It has one of the strongest cash positions in the biotech sector, which could be used to acquire more pipeline assets that could fuel long-term growth. The erythropoiesis-stimulating agents and granulocyte colony-stimulating factor franchise comprise Epogen/Aranesp and Neupogen/Neulasta respectively. Biosimilar drugs are also a key part of Amgen's growth strategy.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.